Search Browse Earnings

Kalaris Therapeutics, Inc.

Nasdaq:KLRS

Biological Products, (No Diagnostic Substances)·BERKELEY HEIGHTS, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$165,000

FY 2020

Adj. EBITDA

-$199.5M

-120910.9% margin

FY 2024

Net Income

-$190.4M

-115404.8% margin

FY 2024

EPS (Diluted)

-$42.09

FY 2024

Stock Price

$9.78

-2.7%

2026-03-10

52W Range

$2.14 – $12.90

P/E Ratio

-0.2x

Market Cap

$182.8M

Cash

$90.1M

FY 2024

Total Debt

—

Net Cash

$90.1M

FY 2020

Enterprise Value

$92.7M

Debt / EBITDA

0.5x

FY 2020

EV / EBITDA

-0.5x

Employees

—